Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Dicerna, Flush With Cash, Is Back To The Drawing Board

Jun 13 2017

• By Jessica Merrill

PCR strip test tubes and micropipette in genetics laboratory. Toned photo

Related Content

Does Alnylam Lift All Oligo Boats? The Dicerna IPO

Feb 14 2014

Regulus HCV Candidate Is Out, But New CEO Has BD Pedigree

Jun 13 2017

RNA Therapeutics Near A Tipping Point, Says Silence’s CEO

Jan 10 2017

Novartis RNA pullback gives biotech stocks whiplash

Apr 15 2014

Related Companies

Dicerna Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Biogen, Inc.

Sarepta Therapeutics, Inc.

Alnylam Pharmaceuticals Inc.

Regulus Therapeutics Inc.

Additional Topics

Platform Technologies Research & Development BioPharmaceutical

More from R&D

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window